EXACT Sciences Corp. Hits New 52-Week High of $104.98

EXACT Sciences Corp., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 104.98 on March 20, 2026. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 144.6%, significantly outpacing the S&P 500's growth of 14.9% during the same period. The company's market capitalization stands at approximately USD 19,824 million, reflecting its solid position within the industry. Despite being loss-making, the stock's performance metrics indicate a notable trajectory, with a debt-to-equity ratio of 0.58. However, the return on equity remains at -6.55%, and the price-to-book ratio is reported at 8.26, suggesting that investors are valuing the company at a premium relative to its book value. With a 52-week low of USD 38.81, the recent high marks a significant turnaround for EXACT Sciences Corp., highlighting its evolving market dynamics and potential resilience in the competitive landscape of pharmaceuticals and biotechnology.